Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/29/2007 4:52:13 PM
	Read Replies (1) of 3044

The best is yet to be [Boronate] 29-Jun-07 11:02 am The frontline results shown in Greece look fantastic. Interim results are expected before or at ASH for two of the PIII front-line registration-enabling trials. Those data should confirm the data from the smaller trials. The data are quite mature in that they are survival rates that had been followed at least 2-4 years. In my opinion, the new data at ASH has the chance to establish unequivocally that Velcade is the best agent in frontline from a clinical standpoint. It is true that it is less convenient than a pill but no doctors will forego a superior treatment for convenience. With MM, strong patient supporting organizations will never go for that either. Given that Velcade prescription has gone up substantially in the past quarter and the new frontline results, I expect that upgrades will come after quarterly conference if not before. It has been a long and painful journey with this stock. I do feel that finally I can say: "Grow old along with me, the best is yet to be". messages.finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next